Human papillomaviruses and cancer

Radiotherapy and Oncology

Volumn 108, Issue 3, 2013, Pages 397-402

  Haedicke, Juliane ^a   Iftner, Thomas ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alpha HPV; Beta HPV; E6; HPV vaccine; Nonmelanoma; Oropharyngeal; Papillomaviruses; Tonsillar

Indexed keywords

CISPLATIN; DOUBLE STRANDED DNA; IMIQUIMOD; PROTEIN E6; PROTEIN E7; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT VACCINE; TOPOTECAN; UBIQUITIN PROTEIN LIGASE E3; WART VIRUS VACCINE; XRCC1 PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT CHEMORADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE PROGRESSION; DISEASE ASSOCIATION; DNA REPAIR; EPIDERMODYSPLASIA VERRUCIFORMIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOSUPPRESSIVE TREATMENT; LOW LEVEL LASER THERAPY; NEOPLASM; NONHUMAN; NONMELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; OROPHARYNX CANCER; PERSISTENT INFECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SKIN CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TONSIL CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS;

ALPHA-HPV; BETA-HPV; E6; HPV VACCINE; NONMELANOMA; OROPHARYNGEAL; PAPILLOMAVIRUSES; TONSILLAR;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; SKIN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84887022769     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.06.004     Document Type: Review

References (86)

1. R. Accardi, W. Dong, and A. Smet Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73 EMBO Rep 7 2006 334 340
2. R. Accardi, R. Rubino, and M. Scalise E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1 J Virol 85 2011 8208 8216
3. K. Andersson, T. Waterboer, and R. Kirnbauer Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions Cancer Epidemiol Biomarkers Prev 17 2008 189 195
4. K.M. Applebaum, C.S. Furniss, and A. Zeka Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer J Natl Cancer Inst 99 2007 1801 1810
5. M. Arbyn, X. Castellsague, and S. de Sanjose Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2011 2675 2686
6. K.A. Ault Human papillomavirus vaccines and the potential for cross-protection between related HPV types Gynecol Oncol 107 2007 S31 S33
7. L. Banks, C. Edmonds, and K.H. Vousden Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells Oncogene 5 1990 1383 1389
8. K.M. Bedard, M.P. Underbrink, H.L. Howie, and D.A. Galloway The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes J Virol 82 2008 3894 3902
9. R.A. Cardone, G. Busco, and M.R. Greco HPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha PloS One 3 2008 e3529
10. X. Castellsague, N. Munoz, and P. Pitisuttithum End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age Br J Cancer 105 2011 28 37
11. A.K. Chaturvedi, E.A. Engels, W.F. Anderson, and M.L. Gillison Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States J Clin Oncol 26 2008 612 619
12. F. Ciccolini, G. Dipasquale, F. Carlotti, L. Crawford, and M. Tommasino Functional-studies of E7 proteins from different Hpv types Oncogene 9 1994 2633 2638
13. M.W. Cobb Human papillomavirus infection J Am Acad Dermatol 22 1990 547 566
14. V. Cogliano, R. Baan, and K. Straif Carcinogenicity of human papillomaviruses Lancet Oncol 6 2005 204
15. G. D'Souza, A.R. Kreimer, and R. Viscidi Case-control study of human papillomavirus and oropharyngeal cancer N Engl Med 356 2007 1944 1956
16. R. Davies, R. Hicks, T. Crook, J. Morris, and K. Vousden Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation J Virol 67 1993 2521 2528
17. E.M. de Villiers, C. Fauquet, T.R. Broker, H.U. Bernard, and H. zur Hausen Classification of papillomaviruses Virology 324 2004 17 27
18. M. Dubina, and G. Goldenberg Viral-associated nonmelanoma skin cancers: a review Am J Dermatopathol 31 2009 561 573
19. J.A. Engelman, and L.C. Cantley A sweet new role for EGFR in cancer Cancer Cell 13 2008 375 376
20. S.C. Fausch, D.M. Da Silva, and W.M. Kast Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res 63 2003 3478 3482
21. J. Fertey, J. Hurst, E. Straub, A. Schenker, T. Iftner, and F. Stubenrauch Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8-E2C proteins and can also be achieved by an artificial repressor protein J Virol 85 2011 2918 2926
22. O. Forslund, T. Iftner, and K. Andersson Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma J Infect Dis 196 2007 876 883
23. A. Frega, L. Lorenzon, and M. Bononi Evaluation of E6 and E7 mRNA expression in HPV DNA positive breast cancer Eur J Gynaecol Oncol 33 2012 164 167
24. T. Ganzenmueller, M. Matthaei, and P. Muench The E7 protein of the cottontail rabbit papillomavirus immortalizes normal rabbit keratinocytes and reduces pRb levels, while E6 cooperates in immortalization but neither degrades p53 nor binds E6AP Virology 372 2008 313 324
25. G. Giaccone, and Y. Wang Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors Cancer Treat Rev 37 2011 456 464
26. B.A. Glaunsinger, S.S. Lee, M. Thomas, L. Banks, and R. Javier Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins Oncogene 19 2000 5270 5280
27. L. Hammarstedt, D. Lindquist, and H. Dahlstrand Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer Int J Cancer 119 2006 2620 2623
28. M. Hoffmann, E.S. Quabius, and S. Tribius Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor Oncol Rep 29 2013 1962 1968
29. H.L. Howie, J.I. Koop, and J. Weese Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association PLoS Pathog 7 2011 e1002211
30. J.M. Huibregtse, M. Scheffner, and P.M. Howley A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18 EMBO J 10 1991 4129 4135
31. A. Iftner, S.J. Klug, and C. Garbe The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors Cancer Res 63 2003 7515 7519
32. T. Iftner, M. Elbel, and B. Schopp Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1 EMBO J 21 2002 4741 4748
33. M. Israel, and L. Schwartz The metabolic advantage of tumor cells Mol Cancer 10 2011 70
34. S. Jeckel, E. Huber, F. Stubenrauch, and T. Iftner A transactivator function of cottontail rabbit papillomavirus e2 is essential for tumor induction in rabbits J Virol 76 2002 11209 11215
35. M. Jing, J. Bohl, N. Brimer, M. Kinter, and S.B. Vande Pol Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins J Virol 81 2007 2231 2239
36. K.M. Johnson, R.C. Kines, J.N. Roberts, D.R. Lowy, J.T. Schiller, and P.M. Day Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus J Virol 83 2009 2067 2074
37. S.N. Khleif, J. DeGregori, and C.L. Yee Inhibition of cyclin d-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity Proc Natl Acad Sci USA 93 1996 4350 4354
38. T. Kiyono, A. Hiraiwa, M. Fujita, Y. Hayashi, T. Akiyama, and M. Ishibashi Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein Proc Natl Acad Sci USA 94 1997 11612 11616
39. S.K. Kjaer, K. Frederiksen, C. Munk, and T. Iftner Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence J Natl Cancer Inst 102 2010 1478 1488
40. R. Klaes, S.M. Woerner, and R. Ridder Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes Cancer Res 59 1999 6132 6136
41. A.J. Klingelhutz, S.A. Foster, and J.K. McDougall Telomerase activation by the E6 gene product of human papillomavirus type 16 Nature 380 1996 79 82
42. J.P. Klussmann, E. Gultekin, and S.J. Weissenborn Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus Am J Pathol 162 2003 747 753
43. E. Koslabova, E. Hamsikova, and M. Salakova Markers of HPV infection and survival in patients with head and neck tumours Int J Cancer 2013
44. A.R. Kreimer, G.M. Clifford, P. Boyle, and S. Franceschi Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review Cancer Epidemiol Biomarkers Prev 14 2005 467 475
45. B. Kumar, K.G. Cordell, and J.S. Lee EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer J Clin Oncol 26 2008 3128 3137
46. E.W. Lam, J.D. Morris, R. Davies, T. Crook, R.J. Watson, and K.H. Vousden HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes EMBO J 13 1994 871 878
47. S.S. Lee, B. Glaunsinger, F. Mantovani, L. Banks, and R.T. Javier Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins J Virol 74 2000 9680 9693
48. S.S. Lee, R.S. Weiss, and R.T. Javier Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein Proc Natl Acad Sci USA 94 1997 6670 6675
49. N. Leiprecht, C. Munoz, and I. Alesutan Regulation of Na(+)-coupled glucose carrier SGLT1 by human papillomavirus 18 E6 protein Biochem Biophys Res Commun 404 2011 695 700
50. K. Li, X. Jin, and Y. Fang Correlation between physical status of human papilloma virus and cervical carcinogenesis J Huazhong Univ Sci Technol Med Sci 32 2012 97 102
51. L. Marklund, and L. Hammarstedt Impact of HPV in oropharyngeal cancer J Oncol 2011 2011 509036
52. S. Marur, G. D'Souza, W.H. Westra, and A.A. Forastiere HPV-associated head and neck cancer: a virus-related cancer epidemic Lancet Oncol 11 2010 781 789
53. X. Mayol, J. Garriga, and X. Grana G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4 Oncogene 13 1996 237 246
54. M.E. McLaughlin-Drubin, and K. Munger Oncogenic activities of human papillomaviruses Virus Res 143 2009 195 208
55. H. Mellin Dahlstrand, D. Lindquist, and L. Bjornestal P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma Anticancer Res 25 2005 4375 4383
56. K. Moberg, M.A. Starz, and J.A. Lees E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry Mol Cell Biol 16 1996 1436 1449
57. D.H. Moore Chemotherapy for recurrent cervical carcinoma Curr Opin Oncol 18 2006 516 519
58. M.P. Morrow, J. Yan, and N.Y. Sardesai Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer Expert Rev Vaccines 12 2013 271 283
59. P. Muench, T. Hiller, S. Probst, A.M. Florea, F. Stubenrauch, and T. Iftner Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes Virology 387 2009 380 387
60. P. Muench, S. Probst, and J. Schuetz Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis Cancer Res 70 2010 6913 6924
61. K. Munger, B.A. Werness, N. Dyson, W.C. Phelps, E. Harlow, and P.M. Howley Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product EMBO J 8 1989 4099 4105
62. N. Munoz, F.X. Bosch, and S. de Sanjose Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527
63. S. Nakagawa, and J.M. Huibregtse Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase Mol Cell Biol 20 2000 8244 8253
64. J.A. Neville, E. Welch, and D.J. Leffell Management of nonmelanoma skin cancer in 2007 Nat Clin Pract Oncol 4 2007 462 469
65. R.M. Richards, D.R. Lowy, J.T. Schiller, and P.M. Day Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection Proc Natl Acad Sci USA 103 2006 1522 1527
66. E. Rotnaglova, R. Tachezy, and M. Salakova HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers Int J Cancer 129 2011 101 110
67. C. Rudlowski, A.J. Becker, W. Schroder, W. Rath, R. Buttner, and M. Moser GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer Am J Clin Pathol 120 2003 691 698
68. J. Ruzevick, A. Olivi, and W.H. Westra Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer J Neuro-Oncol 112 2013 449 454
69. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
70. M. Scheffner, B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 Cell 63 1990 1129 1136
71. M. Schelhaas, B. Shah, and M. Holzer Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis PLoS Pathog 8 2012 e1002657
72. M. Schiffman, G. Clifford, and F.M. Buonaguro Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline Infect Agents Cancer 4 2009 8
73. A. Schmitt, J.B. Harry, B. Rapp, F.O. Wettstein, and T. Iftner Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1 J Virol 68 1994 7051 7059
74. K. Shigehara, T. Sasagawa, and S. Kawaguchi Etiologic role of human papillomavirus infection in bladder carcinoma Cancer 117 2011 2067 2076
75. R. Storey, J. Joh, A. Kwon, A.B. Jenson, S.J. Ghim, and G.H. Kloecker Detection of immunoglobulin G against E7 of human papillomavirus in non-small-cell lung cancer J Oncol 2013 2013 240164
76. J.T. Syverton The pathogenesis of the rabbit papilloma-to-carcinoma sequence Ann NY Acad Sci 54 1952 1126 1140
77. M. Thomas, and L. Banks Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types J Gen Virol 80 1999 1513 1517
78. M. Thomas, and L. Banks Inhibition of Bak-induced apoptosis by HPV-18 E6 Oncogene 17 1998 2943 2954
79. M.P. Underbrink, H.L. Howie, K.M. Bedard, J.I. Koop, and D.A. Galloway E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation J Virol 82 2008 10408 10417
80. R.A. van Boerdonk, J.M. Daniels, and E. Bloemena High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 8 2013 711 718
81. N.A. Wallace, K. Robinson, H.L. Howie, and D.A. Galloway HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage PLoS Pathog 8 2012 e1002807
82. Z. Weihua, R. Tsan, and W.C. Huang Survival of cancer cells is maintained by EGFR independent of its kinase activity Cancer cell 13 2008 385 393
83. S.P. Wilczynski, M. Oft, N. Cook, S.Y. Liao, and T. Iftner Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix Hum Pathol 24 1993 96 102
84. A.W. Woodham, D.M. Da Silva, and J.G. Skeate The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection PloS One 7 2012 e43519
85. R. Zeltner, L.A. Borenstein, F.O. Wettstein, and T. Iftner Changes in RNA expression pattern during the malignant progression of cottontail rabbit papillomavirus-induced tumors in rabbits J Virol 68 1994 3620 3630
86. H. Zimmermann, R. Degenkolbe, H.U. Bernard, and M.J. O'Connor The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300 J Virol 73 1999 6209 6219